[go: up one dir, main page]

WO2013016673A3 - Utilisation de l'expression de dpep1 et tpx2 pour l'évaluation du traitement ou de la durée de survie de patients atteints d'un adénocarcinome du canal pancréatique - Google Patents

Utilisation de l'expression de dpep1 et tpx2 pour l'évaluation du traitement ou de la durée de survie de patients atteints d'un adénocarcinome du canal pancréatique Download PDF

Info

Publication number
WO2013016673A3
WO2013016673A3 PCT/US2012/048655 US2012048655W WO2013016673A3 WO 2013016673 A3 WO2013016673 A3 WO 2013016673A3 US 2012048655 W US2012048655 W US 2012048655W WO 2013016673 A3 WO2013016673 A3 WO 2013016673A3
Authority
WO
WIPO (PCT)
Prior art keywords
patients
survival time
dpep1
evaluating treatment
pancreatic ductal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/048655
Other languages
English (en)
Other versions
WO2013016673A2 (fr
Inventor
Syed Perwez HUSSAIN
Geng Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of WO2013016673A2 publication Critical patent/WO2013016673A2/fr
Publication of WO2013016673A3 publication Critical patent/WO2013016673A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé d'utilisation des niveaux d'expression de la dipeptidase 1 (DPEP1) pour l'évaluation du traitement et/ou de la durée de survie de patients atteints d'un adénocarcinome du canal pancréatique (PDAC), comprenant le dosage des niveaux d'expression de DPEP1 et de la protéine de ciblage pour Xklp2 (TPX2) dans le tissu de PDAC du patient, et l'évaluation du traitement et/ou de la survie, sur la base des niveaux de PDAC de DPEP1 et TPX2 mesurés chez le patient.
PCT/US2012/048655 2011-07-27 2012-07-27 Utilisation de l'expression de dpep1 et tpx2 pour l'évaluation du traitement ou de la durée de survie de patients atteints d'un adénocarcinome du canal pancréatique Ceased WO2013016673A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161512302P 2011-07-27 2011-07-27
US61/512,302 2011-07-27

Publications (2)

Publication Number Publication Date
WO2013016673A2 WO2013016673A2 (fr) 2013-01-31
WO2013016673A3 true WO2013016673A3 (fr) 2013-05-10

Family

ID=46881143

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/048655 Ceased WO2013016673A2 (fr) 2011-07-27 2012-07-27 Utilisation de l'expression de dpep1 et tpx2 pour l'évaluation du traitement ou de la durée de survie de patients atteints d'un adénocarcinome du canal pancréatique

Country Status (1)

Country Link
WO (1) WO2013016673A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006024283A2 (fr) * 2004-08-31 2006-03-09 Technische Universität Dresden Composes et procedes pour traiter, diagnostiquer et pronostiquer des maladies pancreatiques
WO2006066916A1 (fr) * 2004-12-23 2006-06-29 Roche Diagnostics Gmbh Utilisation de dipeptidase microsomale comme marqueur du cancer colorectal
US20070148679A1 (en) * 2005-12-14 2007-06-28 Canon Kabushiki Kaisha Gene set used for examination of Colon cancer
WO2010100899A1 (fr) * 2009-03-02 2010-09-10 株式会社ジーンサイエンス Procédé de test génétique pour le cancer par analyse de l'expression d'un gène lié au cancer à l'aide de monocytes contenus dans un échantillon de sang
US20110171633A1 (en) * 2010-01-11 2011-07-14 Wayne Cowens Method to use gene expression to determine likelihood of clinical outcome of renal cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006024283A2 (fr) * 2004-08-31 2006-03-09 Technische Universität Dresden Composes et procedes pour traiter, diagnostiquer et pronostiquer des maladies pancreatiques
WO2006066916A1 (fr) * 2004-12-23 2006-06-29 Roche Diagnostics Gmbh Utilisation de dipeptidase microsomale comme marqueur du cancer colorectal
US20070148679A1 (en) * 2005-12-14 2007-06-28 Canon Kabushiki Kaisha Gene set used for examination of Colon cancer
WO2010100899A1 (fr) * 2009-03-02 2010-09-10 株式会社ジーンサイエンス Procédé de test génétique pour le cancer par analyse de l'expression d'un gène lié au cancer à l'aide de monocytes contenus dans un échantillon de sang
US20110171633A1 (en) * 2010-01-11 2011-07-14 Wayne Cowens Method to use gene expression to determine likelihood of clinical outcome of renal cancer

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
AGUIRRE A J ET AL: "High resolution characterization of pancreatic adenocarcinoma genome", 15 June 2004 (2004-06-15), XP002689674, Retrieved from the Internet <URL:http://www.pnas.org/content/suppl/2004/05/27/0402932101.DC1/02932Table5.pdf> [retrieved on 20121221] *
AGUIRRE A J ET AL: "High resolution characterization of pancreatic adenocarcinoma genome", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 101, no. 24, 15 June 2004 (2004-06-15), pages 9067 - 9072, XP002566727, ISSN: 0027-8424, DOI: 10.1073/PNAS.0402932101 *
ANDREW R GREEN ET AL: "Loss of expression of chromosome 16q genes DPEP1 and CTCF in lobular carcinoma in situ of the breast", BREAST CANCER RESEARCH AND TREATMENT, KLUWER ACADEMIC PUBLISHERS, BO, vol. 113, no. 1, 23 January 2008 (2008-01-23), pages 59 - 66, XP019639946, ISSN: 1573-7217 *
AUSTRUY E ET AL: "ISOLATION OF KIDNEY COMPLEMENTARY DNAS DOWN-EXPRESSED IN WILMS' TUMOR BY A SUBTRACTIVE HYBRIDIZATION APPROACH", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 53, no. 12, 15 June 1993 (1993-06-15), pages 2888 - 2894, XP008054099, ISSN: 0008-5472 *
CAMPAGNA D. ET AL.: "Gene Expression Profiles Associated with Advanced Pancreatic Cancer", 28 July 2007 (2007-07-28), XP002689673, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2480531/bin/ijcep0001-0032-SD1.xls> [retrieved on 20121221] *
CAMPAGNA DOMENICO ET AL: "Gene Expression Profiles Associated with Advanced Pancreatic Cancer", INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, vol. 1, no. 1, 28 July 2007 (2007-07-28), pages 32 - 43, XP002689672, ISSN: 1936-2625 *
CRNOGORAC-JURCEVIC TATJANA ET AL: "Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent", JOURNAL OF PATHOLOGY, JOHN WILEY & SONS LTD, GB, vol. 201, no. 1, 1 September 2003 (2003-09-01), pages 63 - 74, XP002425775, ISSN: 0022-3417, DOI: 10.1002/PATH.1418 *
GENG ZHANG ET AL: "DPEP1 Inhibits Tumor Cell Invasiveness, Enhances Chemosensitivity and Predicts Clinical Outcome in Pancreatic Ductal Adenocarcinoma", PLOS ONE, vol. 7, no. 2, 1 January 2012 (2012-01-01), pages e31507, XP055048456, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0031507 *
LOGSDON C D ET AL: "Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 63, 15 May 2003 (2003-05-15), pages 2649 - 2657, XP002982644, ISSN: 0008-5472 *
MCIVER C M ET AL: "Dipeptidase 1: a candidate tumor-specific molecular marker in colorectal carcinoma", CANCER LETTERS, NEW YORK, NY, US, vol. 209, no. 1, 8 June 2004 (2004-06-08), pages 67 - 74, XP002368418, ISSN: 0304-3835, DOI: 10.1016/J.CANLET.2003.11.033 *
NAKAMURA TORU ET AL: "Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection", ONCOGENE, NATURE PUBLISHING GROUP, GB, vol. 23, no. 13, 25 March 2004 (2004-03-25), pages 2385 - 2400, XP002331614, ISSN: 0950-9232, DOI: 10.1038/SJ.ONC.1207392 *
PHILIP PHILIP A ET AL: "Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 20 NOV 2009, vol. 27, no. 33, 20 November 2009 (2009-11-20), pages 5660 - 5669, XP009165911, ISSN: 1527-7755 *
S. L. WARNER ET AL: "Validation of TPX2 as a Potential Therapeutic Target in Pancreatic Cancer Cells", CLINICAL CANCER RESEARCH, vol. 15, no. 21, 1 November 2009 (2009-11-01), pages 6519 - 6528, XP055048484, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-09-0077 *
WEIZMANN INSTITUTE: "Query for probes for DPEP1 on Affymetrix arrays.", 21 December 2012 (2012-12-21), XP002689675, Retrieved from the Internet <URL:http://genecards.weizmann.ac.il/cgi-bin/geneannot/GA_search.pl> [retrieved on 20121221] *

Also Published As

Publication number Publication date
WO2013016673A2 (fr) 2013-01-31

Similar Documents

Publication Publication Date Title
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
MX2016006252A (es) Tratamiento o prevencion de afecciones pulmonares con monoxido de carbono.
EP2076172A4 (fr) Utilisation de techniques de raman cohérentes dans des buts de diagnostic médical et thérapeutiques, et leurs techniques de calibrage
WO2012048241A3 (fr) Procédé et appareil pour la thermothérapie du cancer de la peau
WO2011156755A3 (fr) Instruments adaptés aux patients
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
MX376652B (es) Método para determinar la eficacia de una terapia con fármacos de direccionamiento a glipicano 3 (gpc3) contra cáncer.
MX2009010899A (es) Prediccion de la supervivencia al post-tratamiento en pacientes de cancer con micro-rnas.
WO2012027402A3 (fr) Instruments adaptés à un patient
AU2012343270A8 (en) Method and apparatus for verifying compliance with dental appliance therapy
WO2010141803A3 (fr) Poumon bioartificiel
TN2011000176A1 (en) Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
GB2467467B (en) TAZ/WWTR1 for diagnosis and treatment of cancer
WO2010091049A3 (fr) Diagnostic et traitement du cancer
WO2008021183A3 (fr) Procédés d&#39;identification, d&#39;évaluation, et de traitement de patients soumis à une thérapie anticancéreuse
WO2010085542A3 (fr) Biomarqueurs associés à la dégénérescence maculaire liée à l&#39;âge (dmla)
MX347871B (es) Biomarcadores de citoquina como marcadores predictivos de respuesta clínica para acetato de glatirámero.
MX2014002034A (es) Medicion de aireacion no invasiva.
WO2014043633A8 (fr) Utilisation de e-cadhérine et de vimentine pour la sélection de patients répondant à un traitement
WO2014038682A3 (fr) Méthode de diagnostic et thérapeutique du cancer ciblant des molécules exprimées dans des cellules souches cancéreuses
GB2465907A (en) VHZ for diagnosis and treatment of cancer
WO2012109233A3 (fr) Procédés de prédiction du risque de récidive chez des patients atteints d&#39;un cancer du sein
UA105940C2 (uk) Лікарська комбінація з теоброміном та опіатом і її використання в лікуванні кашлю
Gritzan et al. Diagnostics and intensive therapy of acute respiratory distress syndrome. FAR's clinical guidelines
PH12012501203A1 (en) Combination of theobromine with a decongestant and its use for the treatment of cough

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12761827

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12761827

Country of ref document: EP

Kind code of ref document: A2